MediWound (MDWD) Wins More Federal Money, Revenue Down 40%

Why This Matters Now

On September 22, 2026, MediWound Ltd. (NASDAQ: MDWD) announced that the US Department of War had awarded it an additional $3.3 million in non-dilutive funding to advance a room-temperature-stable formulation of NexoBrid. Per the company’s release, that brings the total program budget to $21.8 million, following earlier awards that stood at $14.4 million at the end of 2023 and a further addition in 2025.

Non-dilutive is the important word. A federal agency paying for development work is money that does not come from issuing shares, which at a company with 12.91 million shares outstanding matters more than the headline figure suggests.

The award also has a specific technical purpose worth understanding. NexoBrid currently ships refrigerated and must be stored between 2 and 8 degrees Celsius. That is workable in a hospital burn unit and impractical in a field setting. The funding covers the step between an approved hospital product and one that can be carried where refrigeration does not exist, which explains why a defense agency rather than a health agency is paying for it.

Eight days earlier, on September 14, the independent Data and Safety Monitoring Board completed its pre-specified periodic safety review of the ongoing Phase III VALUE study for EscharEx and recommended the study continue without modification, identifying no safety concerns.

Shares traded at $13.80 on September 22, up 3.68%, against a 52-week range of $12.52 to $20.03. The stock sits close to the bottom of that range.

A note on sourcing. Promotional articles about this company are currently circulating through sponsored investor-relations distributors. This piece is built from the company’s own releases on GlobeNewswire, its reported results, and market data. Readers encountering bullish coverage of MediWound should check the byline before treating it as editorial.

What The Company Does

MediWound makes enzymatic products that remove dead tissue without surgery. The clinical term is debridement: clearing dead tissue so a wound can heal.

NexoBrid is the approved product. It is a topical gel derived from an enzyme found in pineapple stems, applied once for four hours, which dissolves eschar, the hard dead tissue that forms over a severe burn, while leaving healthy skin intact. The conventional alternative is surgical excision, which requires an operating room, a surgeon and anesthesia. NexoBrid works at the bedside. It is FDA-approved, approved in 45 countries, and held in the US Strategic National Stockpile.

EscharEx is the pipeline product, the same bromelain-based approach aimed at chronic wounds such as venous leg ulcers and diabetic foot ulcers rather than burns. It is in a Phase III trial called VALUE. Chronic wounds are a far larger market than severe burns, which is why the company’s valuation rests more on EscharEx than on the product it already sells.

The company is headquartered in Yavne, Israel, listed on Nasdaq since March 2014, and employs 121 people. North American distribution of NexoBrid runs through Vericel (NASDAQ: VCEL).

The Bull Case

Federal money keeps arriving, across agencies and across administrations. The Department of War program has been topped up repeatedly and now stands at $21.8 million. Separately, per the company’s April 2, 2026 release, BARDA awarded commercial partner Vericel a ten-year contract for NexoBrid valued at up to $197 million against a $35 million base period. Two different federal buyers, one procurement and one development, both returning. That is a harder endorsement to manufacture than a press release.

The Phase III trial passed its safety review. The DSMB recommendation on September 14 that VALUE continue without modification is a genuine de-risking event. It does not indicate efficacy, and readers should not read it as such, but a trial halted on safety grounds is the most common way a program of this kind dies, and that outcome has now been ruled out at this checkpoint. Interim assessment and enrolment completion are expected by the end of the first quarter of 2027.

Second quarter revenue beat substantially. Per the August 13, 2026 results, Q2 revenue was $4.57 million against a $2.59 million consensus, and the company described record US NexoBrid sales. Against $1.48 million in the first quarter, that is a tripling in one quarter, which is the direction the full-year guidance requires.

The Bear Case

• The guidance requires the second half to be roughly three times the first. Revenue was $1.48 million in Q1 and $4.57 million in Q2, totalling $6.05 million. Full-year guidance of $24 million to $26 million therefore implies between $18 million and $20 million across the third and fourth quarters. Management attributes that to expected contributions from the Vericel master services agreement and other government-funded programs. The arithmetic is not impossible. It is a very large step, it has not yet been demonstrated in a reported quarter, and it rests on the timing of government orders rather than on commercial demand.
• Trailing revenue is going backwards. Revenue over the last twelve months was $11.86 million, down 40.3%. Full year 2025 revenue was $16.96 million, itself down 16.14% from $20.22 million in 2024. That is two consecutive periods of decline at a company whose forward case depends on a sharp reacceleration.
• The second quarter loss was far worse than expected. Reported loss per share was $1.36 against a 77 cent consensus, despite the revenue beat. Trailing net income is negative $20.18 million on $11.86 million of revenue, and trailing loss per share is $2.25. A company can beat on revenue and miss badly on the bottom line in the same quarter, and this one did.
• The share count is very small and the stock is thinly traded. With 12.91 million shares outstanding and volume of 36,812 on the day of the award, daily dollar volume runs near $508,000. That clears the threshold below which a position cannot be exited, but not by much, and a small float means the price moves disproportionately on modest flow in either direction.
• The risk that cuts against this view: six analysts rate the stock Strong Buy with an average target of $30.67, more than double the current price, and Alliance Global raised its target to $27 from $22 on September 16 after the DSMB news. If the second half arrives as guided and VALUE reaches its interim assessment cleanly, the trailing revenue decline becomes a timing artifact of government order schedules and this piece will read as too cautious.

Financial Snapshot

On the balance between the two products: the company sells NexoBrid and is valued on EscharEx. NexoBrid revenue is real, approved and partly government-purchased, and it is running at a level that does not support the market capitalization on its own. EscharEx has no approval, no revenue, and a Phase III trial whose interim assessment is roughly two quarters away. Any reading of this company has to be explicit about which of those two it is buying.

Catalysts To Watch

• Third quarter results, expected November 2026. This is the test. Revenue needs to show the second half ramp beginning, or the full-year guidance becomes difficult to reach in a single quarter.
• EscharEx Phase III interim assessment and enrolment completion, expected by the end of the first quarter of 2027.
• Orders under the Vericel master services agreement, signed under the BARDA contract. The timing of these is what management points to when explaining the shape of the year.
• Progress on the room-temperature formulation funded by the September 22 award, which would widen where NexoBrid can be deployed.
• Any equity raise. With 12.91 million shares outstanding, a financing of meaningful size would move the count materially.

The Bottom Line

MediWound sells an approved product that two separate federal agencies keep paying for, has just cleared a Phase III safety review, and took another $3.3 million of non-dilutive funding this week. None of that is promotional framing. It is documented across company releases and federal contracts.

It also has trailing revenue down 40.3%, a second quarter loss nearly double what analysts expected, and a full-year guidance figure that requires the second half to deliver roughly three times the first. The stock sits near the bottom of its 52-week range while six analysts carry targets more than double the price.

We label this Neutral. The federal validation is real and the revenue trajectory is real, and they say opposite things. The Desk treats the Department of War award as evidence of the product’s standing, not as revenue. What to watch is third quarter results in November 2026, and specifically whether the second half ramp the guidance requires has actually begun.